Last reviewed · How we verify
Vilanterol and Umeclidinium Bromide
Vilanterol is a long-acting beta-2 agonist and umeclidinium bromide is a long-acting muscarinic antagonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
Vilanterol is a long-acting beta-2 agonist and umeclidinium bromide is a long-acting muscarinic antagonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Vilanterol and Umeclidinium Bromide |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) |
| Target | Beta-2 adrenergic receptor; M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Vilanterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and increased cAMP levels. Umeclidinium bromide blocks M3 muscarinic receptors, preventing acetylcholine-induced bronchoconstriction. Together, these complementary mechanisms provide dual bronchodilation for sustained airway opening in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- Immuno-inflammatory Response of Erdosteine in COPD (NA)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
- Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients (PHASE2)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vilanterol and Umeclidinium Bromide CI brief — competitive landscape report
- Vilanterol and Umeclidinium Bromide updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI